Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 212Terminated 68Recruiting 46Active not recruiting 46Withdrawn 18Unknown 9Not yet recruiting 7No longer available 2Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

zilucoplan 1toripalimab 1somapacitan 1rozanolixizumab 1pembrolizumab 1ibrutinib 1futibatinib 1exemestane 1enzalutamide 1durvalumab 1decitabine and cedazuridine drug combination 1cemiplimab 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Tamoxifen 1Robotic Surgical Procedures 1Observation 1Letrozole 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Fulvestrant 1Folfox protocol 1Dexamethasone 1Cisplatin 1Carboplatin 1Bevacizumab 1Anastrozole 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × INDUSTRY × Dexamethasone × Clear all
NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

HuniLife Biotechnology, Inc.

Phase 1/2 Enrolling by invitation
21 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡